Onyx栓塞联合立体定向放射外科治疗脑动静脉畸形的匹配队列研究
该多中心回顾性匹配队列研究基于国际放射外科研究基金会1987至2018年数据库,比较Onyx栓塞后SRS与单纯SRS治疗脑AVM的结局。匹配后各53例,两组AVM闭塞率、出血、死亡及放射相关改变均相似,提示术前Onyx栓塞不负面影响SRS结局,但栓塞相关并发症需权衡。
要点
- 术前Onyx栓塞不降低SRS后AVM闭塞率,两组粗闭塞率37.7%对47.2%。
- 匹配后两组闭塞累积概率及出血、死亡、放射相关改变均相似。
- Onyx栓塞相关无症状和有症状并发症率分别为18.9%和9.4%。
核心结论
- 术前Onyx栓塞似乎不负面影响SRS治疗AVM后的结局,反驳了既往认为Onyx栓塞损害SRS诱导闭塞的研究。
研究设计与样本
- 多中心回顾性匹配队列研究,回顾国际放射外科研究基金会AVM数据库1987至2018年数据,按倾向评分1:1匹配。
主要发现
- 匹配后Onyx栓塞联合SRS组与单纯SRS组各53例,AVM闭塞粗率分别为37.7%和47.2%(OR 0.679,p=0.327)。
- 3、4、5、6年闭塞累积概率在联合组为33.7%、44.1%、57.5%、65.7%,单纯SRS组为34.8%、45.5%、59.0%、67.1%(亚风险比0.961,p=0.896)。
- 匹配队列的次要结局包括SRS后出血、全因死亡、放射相关改变和囊肿形成均相似。
- 匹配联合组栓塞相关无症状和有症状并发症率分别为18.9%和9.4%。
关键数值与推荐
- AVM闭塞粗率:联合组37.7%对单纯SRS组47.2%(OR 0.679,p=0.327)。
- AVM闭塞累积概率亚风险比0.961(p=0.896)。
- 栓塞相关无症状并发症18.9%,有症状并发症9.4%。
临床怎么用
- 术前Onyx栓塞可作为大型或血管构筑高危AVM多模式治疗的一部分,但需权衡栓塞相关风险并审慎选择患者。
局限性
- 回顾性研究设计,匹配后样本量较小(每组53例),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigations of the combined effects of neoadjuvant Onyx embolization and stereotactic radiosurgery (SRS) on brain arteriovenous malformations (AVMs) have not accounted for initial angioarchitectural features prior to neuroendovascular intervention. The aim of this retrospective, multicenter matched cohort study is to compare the outcomes of SRS with versus without upfront Onyx embolization for AVMs using de novo characteristics of the preembolized nidus. METHODS: The International Radiosurgery Research Foundation AVM databases from 1987 to 2018 were retrospectively reviewed. Patients were categorized based on AVM treatment approach into Onyx embolization (OE) and SRS (OE+SRS) or SRS alone (SRS-only) cohorts and then propensity score matched in a 1:1 ratio. The primary outcome was AVM obliteration. Secondary outcomes were post-SRS hemorrhage, all-cause mortality, radiological and symptomatic radiation-induced changes (RICs), and cyst formation. Comparisons were analyzed using crude rates and cumulative probabilities adjusted for competing risk of death. RESULTS: The matched OE+SRS and SRS-only cohorts each comprised 53 patients. Crude rates (37.7% vs 47.2% for the OE+SRS vs SRS-only cohorts, respectively; OR 0.679, p = 0.327) and cumulative probabilities at 3, 4, 5, and 6 years (33.7%, 44.1%, 57.5%, and 65.7% for the OE+SRS cohort vs 34.8%, 45.5%, 59.0%, and 67.1% for the SRS-only cohort, respectively; subhazard ratio 0.961, p = 0.896) of AVM obliteration were similar between the matched cohorts. The secondary outcomes of the matched cohorts were also similar. Asymptomatic and symptomatic embolization-related complication rates in the matched OE+SRS cohort were 18.9% and 9.4%, respectively. CONCLUSIONS: Pre-SRS AVM embolization with Onyx does not appear to negatively influence outcomes after SRS. These analyses, based on de novo nidal characteristics, thereby refute previous studies that found detrimental effects of Onyx embolization on SRS-induced AVM obliteration. However, given the risks incurred by nidal embolization using Onyx, this neoadjuvant intervention should be used judiciously in multimodal treatment strategies involving SRS for appropriately selected large-volume or angioarchitecturally high-risk AVMs.
引用
- Chen CJ, Ding D, Lee CC, et al. Stereotactic radiosurgery with versus without prior Onyx embolization for brain arteriovenous malformations. J Neurosurg. 2020. PMID: 33307527. doi:10.3171/2020.7.JNS201731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。